Implementation bottlenecks of real time medication monitoring (evriMED) for improving adherence to anti-TB drugs among people with tuberculosis in Kilimanjaro, Tanzania

Rehema Anenmose Maro; Alan Mtenga; Benson Mtesha; Krisanta Wilhelm; Naomi Lekashingo; Marion Sumari-de Boer; Kennedy Ngowi

doi:10.1016/j.jctube.2023.100409

Implementation bottlenecks of real time medication monitoring (evriMED) for improving adherence to anti-TB drugs among people with tuberculosis in Kilimanjaro, Tanzania

J Clin Tuberc Other Mycobact Dis. 2023 Dec 3:34:100409. doi: 10.1016/j.jctube.2023.100409. eCollection 2024 Feb.

Authors

Rehema Anenmose Maro^{1

2}, Alan Mtenga^{1

2}, Benson Mtesha¹, Krisanta Wilhelm¹, Naomi Lekashingo¹, Marion Sumari-de Boer^{1

3

4

5}, Kennedy Ngowi¹

Affiliations

¹ Kilimanjaro Clinical Research Institute, Moshi, Tanzania.
² Nelson Mandela African Institute of Science and Technology, Arusha, Tanzania.
³ Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
⁴ Kilimanjaro Christian Medical Univesity Collage, Moshi, Tanzania.
⁵ Knowledge, Innovation & Technology Group at Wageningen & University Research, the Netherlands.

Abstract

Introduction: Digital Adherence Tools (DATs), which include real-time medication monitoring and Short Message Service (SMS) reminders, have been reported to improve medication adherence among people with Tuberculosis (TB). Recently, in limited resource settings, DATs have been described as a promising tool to monitor patients' medication behaviour. We aimed to determine implementation bottlenecks of real-time medication monitoring using the evriMED device.

Method: We conducted a research study using a mixed-methods approach, involving both people with TB s and directly observed treatment (DOT) providers who participated in the REMIND-TB trial and utilized the evriMED devices. EvriMED is a medication dispenser with internet connectivity that can send real-time SMS reminders. To gather data, we extracted reports from the Wisepill dashboard, specifically the client status report. This report documented the activity status of all devices, including communication and battery status. Additionally, we conducted in-depth interviews with people with TB and TB care providers who were involved in implementing the Remind TB trial in the Kilimanjaro region. These interviews were guided by the MIDI (Measurement Instrument for Determinants of Innovation), which helps identify the factors influencing the implementation of innovations such as evriMED.

Results: Out of the initial 281 participants who were given devices, 245 completed the 6-month follow-up period. The findings indicate that at month 6, most of the devices (49%) reported battery-related challenges. Additionally, forty devices (14%) had reported more than one incidence of losing communication. Through interviews with participants, we observed that evriMED was perceived as user-friendly, and the people with TB reported high satisfaction as the device facilitated improved medication intake. TB care providers also said that evriMED was a relevant tool to be used by the people with TB. However, during the in-depth interview certain implementation bottlenecks were identified, including network issues, limited training, and low technology knowledge among TB care providers, who found the procedure of using the evriMED to be time-consuming.

Conclusion: Implementation of evriMED was perceived as user-friendly and highly satisfactory by people with TB. Certain implementation bottlenecks were identified as potential barriers to the use of devices. These bottlenecks include network issues, limited training, battery-related challenges and low technological knowledge among TB care providers, which may have contributed to communication loss. Further research may be needed to address these limitations and develop effective strategies to facilitate the successful implementation of evriMED as a tool for improving medication intake among people with TB.

Keywords: Adherence; Real-time monitoring; SMS reminder; Tuberculosis; evriMED.